Skip to main content
D. New Jersey· 6/27/2013

Glynn v. Merck Sharp & Dohme Corp.

Citations

  • 951 F. Supp. 2d 695

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

  • finding preemption based on PAS submission, but recognizing the clear evidence standard is undefined
  • holding conflict preemption is a demanding defense
  • FDA’s denial of drug manufacturer’s requested change to “[precautions” section of label soon after plaintiff’s injury provided clear evidence FDA would have rejected change before injury occurred
  • “Thus, since the FDA rejected Defendant’s PAS, it would not have approved a CBE seeking to add the same language to the label that it just rejected in the PAS.”
  • “Thus, since the FDA rejected Defendant’s PAS, it would not have approved a CBE seeking to add the same language to the label that it just rejected in the PAS_”
  • “Like a PAS, the ‘proposed change must be based on ‘reasonable evidence of an association between a hazard and the drug at issue; however, a causal relationship need not have been definitely established.’ ”

Source: CourtListener parenthetical corpus (CC0).

Judges: Pisano

Read full opinion on CourtListener

Cited by

7 cases in this archive cite this case.

Cites

9 cases in this archive are cited by this case.

Sourced from CourtListener / Free Law Project (CC0).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.